3 Result(s)
within
Kirsten E. J. Wesenhagen
-
Article
Open AccessCerebrospinal fluid proteomics in patients with Alzheimer’s disease reveals five molecular subtypes with distinct genetic risk profiles
Alzheimer’s disease (AD) is heterogenous at the molecular level. Understanding this heterogeneity is critical for AD drug development. Here we define AD molecular subtypes using mass spectrometry proteomics in...
-
Article
Open AccessP-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles
We previously identified four Alzheimer’s disease (AD) subgroups with increasingly higher cerebrospinal fluid (CSF) levels of tau phosphorylated at threonine 181 (p-tau). These subgroups included individuals a...
-
Article
Open AccessFour subgroups based on tau levels in Alzheimer’s disease observed in two independent cohorts
As Alzheimer’s disease (AD) pathology presents decades before dementia manifests, unbiased biomarker cut-points may more closely reflect presence of pathology than clinically defined cut-points. Currently, unb...
